RxDoctor Payments Data

Joelle Kozierowski

Family · Kenmore, NYNPI 1316722770

Payments from drug & device makers

$2,032in general payments, 2019–2025

Across 33 payments — averaging $61.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$495
  • AstraZeneca$359
  • GSK$258
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$168
  • Bayer$158
  • Acadia Pharmaceuticals Inc$125
  • plus $470 from 6 others

What the payments were for

  • Food & beverage$2,032100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,032 in reported general payments places this provider in the 80th percentile of 8,883 family providers in New York.

See all family providers in New York

Medicare billing

Part B allowed, 2024
$29,612
Medicare patients
188
Services billed
381

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide45$45,413
JardianceEmpagliflozin60$40,258
MounjaroTirzepatide23$25,517
Trelegy ElliptaFluticasone/Umeclidin/Vilanter17$13,032
Breo ElliptaFluticasone/Vilanterol13$5,752
SynthroidLevothyroxine Sodium32$2,984
Albuterol Sulfate HfaAlbuterol Sulfate83$2,513
Lantus SolostarInsulin Glargine,hum.Rec.Anlog22$2,133
Atorvastatin Calcium108$1,633
Levothyroxine Sodium119$1,542
Fluticasone Propionate68$1,096
Metoprolol Succinate47$921
Gabapentin35$839
Adacel TdapDiph,pertuss(Acell),tet Vac/Pf11$721
Rosuvastatin Calcium53$707

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$23$25,51723 claims
GSKTrelegy Ellipta, Breo Ellipta$258$18,78530 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 8,883 family providers in New York.

Other family in Kenmore

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →